£2.5M
The financing round includes contributions from Deepbridge Capital, Scottish Enterprise, SIS Ventures, Thairm Bio, and the University of Strathclyde to support clinical trials and commercial expansion.
MD
Microplate Dx
Microplate Dx develops a rapid diagnostic platform to identify effective antibiotic treatments.
Glasgow, UK—Founded 2022
£2.5MTotal raised
Microplate Dx develops a rapid diagnostic platform designed to detect bacterial infections and identify effective antibiotic treatments within minutes. The University of Strathclyde spinout focuses on tackling antimicrobial resistance starting with urinary tract infections.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Microplate Dx's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Stuart Hannah
CEO
Stuart is the founder and chief executive officer of Microplate Dx. He brings academic and research experience from the University of Strathclyde and the École des Mines de Saint-Étienne.
LinkedInDC
Damion Corrigan
CTO
Damion brings academic and founding experience in diagnostics and biosensing platforms from his roles as a professor at the University of Strathclyde, chief scientific officer at Aureum Diagnostics, and chief technology officer at Microplate Dx.
LinkedIn
Paul Hoskisson
CSO
Paul brings academic and commercial microbiology experience from his roles as a founder and Chief Scientific Advisor at Microplate Dx, alongside his position as a Research Chair at the University of Strathclyde.
LinkedIn
Poonam Malik
Chair
Poonam brings life sciences, venture, and board experience from roles including co-founder and Executive Chair of Microplate Dx Limited, Vice President for Business at the Royal Society of Edinburgh, and board positions at Scottish Enterprise and Skills Development Scotland.
LinkedIn